西部超導(688122.SH)一度跌超11% 多股東擬合計減持不超14%
格隆匯7月24日丨科創板一週年之際,個股普遍迎來解禁潮。其中,西部超導(688122.SH)遭遇多名股東減持,股價在今日持續回調,今日跌勢繼續,盤中一度跌11.47%至30.03元,創今年4月30日以來新低,該股自月內高位46.49元回調至今,累跌跌幅已達35%。公司昨日公告,股東中信金屬、深創投、陝西成長新興與陝西成長新材料擬合計減持不超過14%股份。西部超導主要從事高端鈦合金材料和低温超導材料的研發、生產和銷售。公司的主要產品是棒材、絲材、鍛坯、鈮鈦錠棒、鈮鈦超導線材、鈮三錫超導線材、超導磁體、變形高温合金、鑄造和粉末高温合金母合金。公司於去年7月22日以15元在科創板上市。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.